ES2740827T3 - GLUT-1 como receptor de envolturas del HTLV y sus usos - Google Patents

GLUT-1 como receptor de envolturas del HTLV y sus usos Download PDF

Info

Publication number
ES2740827T3
ES2740827T3 ES16197090T ES16197090T ES2740827T3 ES 2740827 T3 ES2740827 T3 ES 2740827T3 ES 16197090 T ES16197090 T ES 16197090T ES 16197090 T ES16197090 T ES 16197090T ES 2740827 T3 ES2740827 T3 ES 2740827T3
Authority
ES
Spain
Prior art keywords
seq
htlv
glut1
polypeptide
polypeptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES16197090T
Other languages
English (en)
Spanish (es)
Inventor
Jean-Luc Battini
Nicolas Manel
Felix Kim
Sandrina Kinet
Naomi Taylor
Marc Sitbon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique
University of Montpellier
Original Assignee
Centre National de la Recherche Scientifique
University of Montpellier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique, University of Montpellier filed Critical Centre National de la Recherche Scientifique
Application granted granted Critical
Publication of ES2740827T3 publication Critical patent/ES2740827T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6045—RNA rev transcr viruses
    • C12N2810/6054—Retroviridae

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Rheumatology (AREA)
ES16197090T 2003-05-02 2004-04-30 GLUT-1 como receptor de envolturas del HTLV y sus usos Expired - Lifetime ES2740827T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03291067 2003-05-02

Publications (1)

Publication Number Publication Date
ES2740827T3 true ES2740827T3 (es) 2020-02-06

Family

ID=33396025

Family Applications (1)

Application Number Title Priority Date Filing Date
ES16197090T Expired - Lifetime ES2740827T3 (es) 2003-05-02 2004-04-30 GLUT-1 como receptor de envolturas del HTLV y sus usos

Country Status (6)

Country Link
US (2) US7642061B2 (enExample)
EP (3) EP1648926B1 (enExample)
JP (1) JP5612239B2 (enExample)
DK (1) DK1648926T3 (enExample)
ES (1) ES2740827T3 (enExample)
WO (1) WO2004096841A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1648926B1 (en) * 2003-05-02 2013-07-03 Centre National De La Recherche Scientifique (Cnrs) Glut-1 as a receptor for htlv envelopes and its uses
US9777044B2 (en) * 2003-05-02 2017-10-03 Centre National De La Recherche Scientifique (Cnrs) GLUT-1 as a receptor for HTLV envelopes and its uses
US20070231260A1 (en) * 2005-09-30 2007-10-04 Xenoport, Inc. Transporter-targeted methods of diagnosis and treatment
WO2010079208A1 (en) * 2009-01-09 2010-07-15 Centre National De La Recherche Scientifique New receptor binding ligands, their use in the detection of cells with biological interest
US8870950B2 (en) 2009-12-08 2014-10-28 Mitral Tech Ltd. Rotation-based anchoring of an implant
WO2012035369A1 (en) * 2010-09-17 2012-03-22 Centre National De La Recherche Scientifique Method for the diagnosis and/or prognosis of inflammatory states
MX2017011615A (es) * 2015-03-10 2018-04-11 Univ Columbia Construcciones de vectores virales adeno-asociados de glut1 recombinantes y métodos relacionados para restablecer la expresión de glut1.
EP3861350A1 (en) 2018-10-05 2021-08-11 Metafora Biosystems Use of ligands derived from receptor-binding domain of porcine endogenous retrovirus type b for diagnosing smvt-related diseases
CN113527429B (zh) * 2020-04-15 2024-04-16 辽宁中健医药科技有限公司 人肝癌细胞特异结合多肽及其用途
WO2026041773A1 (en) * 2024-08-23 2026-02-26 Metafora Biosystems Improved glut1-binding polypeptides

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614366A (en) * 1986-12-31 1997-03-25 Genelabs Technologies, Inc. HTLV-I peptide antigens and kit
JPH01501939A (ja) 1987-01-28 1989-07-06 オーソ・フアーマシユーチカル・コーポレーシヨン 免疫抑制ペプチドおよび使用法
WO1996021727A1 (en) 1995-01-13 1996-07-18 Virogenetics Corporation Immunogenic compositions containing recombinant attenuated poxviruses expressing htlv antigens
US5698410A (en) * 1995-06-07 1997-12-16 Mount Sinai School Of Medicine Of The City University Of New York Highly sensitive immunocytochemical method for diagnosis of malignant effusions
US5897991A (en) * 1995-06-07 1999-04-27 The Mount Sinai Medical Center Highly sensitive immunocytochemical method for diagnosis of malignant effusions
EP0857212A2 (en) 1995-10-23 1998-08-12 Board Of Regents, The University Of Texas System Methods and compositions comprising glut-2 and glut-2 chimeras
CA2262007A1 (en) * 1996-07-22 1998-01-29 The Rockefeller University Env-glycoprotein vaccine for protection of htlv-i and -ii infection
WO1999045920A2 (en) 1998-03-13 1999-09-16 Johns Hopkins University School Of Medicine The use of a protein tyrosine inhibitor such as genistein in the treatment of diabetic retinopathy or ocular inflammation
AU3991499A (en) 1998-05-15 1999-12-06 Joslin Diabetes Center Independent regulation of basal and insulin-stimulated glucose transport
EP1648926B1 (en) * 2003-05-02 2013-07-03 Centre National De La Recherche Scientifique (Cnrs) Glut-1 as a receptor for htlv envelopes and its uses

Also Published As

Publication number Publication date
US8945583B2 (en) 2015-02-03
JP5612239B2 (ja) 2014-10-22
EP2610265A1 (en) 2013-07-03
EP1648926A1 (en) 2006-04-26
EP2610265B1 (en) 2016-11-16
DK1648926T3 (da) 2013-10-14
EP3168227A1 (en) 2017-05-17
WO2004096841A1 (en) 2004-11-11
JP2007535293A (ja) 2007-12-06
US20080268424A1 (en) 2008-10-30
US7642061B2 (en) 2010-01-05
EP3168227B1 (en) 2019-05-22
EP1648926B1 (en) 2013-07-03
WO2004096841A8 (en) 2006-01-19
US20100056448A1 (en) 2010-03-04

Similar Documents

Publication Publication Date Title
US8945583B2 (en) GLUT-1 as a receptor for HTLV envelopes and its uses
Braaten et al. Cyclophilin A is required for the replication of group M human immunodeficiency virus type 1 (HIV-1) and simian immunodeficiency virus SIV (CPZ) GAB but not group O HIV-1 or other primate immunodeficiency viruses
Maurice et al. Efficient gene transfer into human primary blood lymphocytes by surface-engineered lentiviral vectors that display a T cell–activating polypeptide
Hoshino Cellular factors involved in HTLV-1 entry and pathogenicit
Sharma et al. Efficient infection of a human T-cell line and of human primary peripheral blood leukocytes with a pseudotyped retrovirus vector.
Constantinescu et al. Activation of the erythropoietin receptor by the gp55‐P viral envelope protein is determined by a single amino acid in its transmembrane domain
Shuh et al. The human T‐cell leukemia virus type 1 (HTLV‐1): New insights into the clinical aspects and molecular pathogenesis of adult t‐cell leukemia/lymphoma (ATLL) and tropical spastic paraparesis/HTLV‐associated myelopathy (TSP/HAM)
Hendriks et al. Biology and novel treatment options for XLA, the most common monogenetic immunodeficiency in man
Dimitrov et al. A mechanism of resistance to HIV-1 entry: inefficient interactions of CXCR4 with CD4 and gp120 in macrophages
Tang et al. Human immunodeficiency virus type 1 N-terminal capsid mutants containing cores with abnormally high levels of capsid protein and virtually no reverse transcriptase
Le Blanc et al. Multiple functions for the basic amino acids of the human T-cell leukemia virus type 1 matrix protein in viral transmission
Miller et al. Intravirion generation of the C-terminal core domain of HIV-1 Nef by the HIV-1 protease is insufficient to enhance viral infectivity
Firsching et al. Measles virus spread by cell-cell contacts: uncoupling of contact-mediated receptor (CD46) downregulation from virus uptake
Jones et al. Induction of human T cell leukemia virus type I receptors on quiescent naive T lymphocytes by TGF-β
US20180002383A1 (en) Glut-1 as a receptor for htlv envelopes and its uses
Camaur et al. Human immunodeficiency virus matrix tyrosine phosphorylation: characterization of the kinase and its substrate requirements
Kira et al. Sequence heterogeneity of HTLV‐I proviral DNA in the central nervous system of patients with HTLV‐I–associated myelopathy
Yanagi The cellular receptor for measles virus—elusive no more
Manel et al. HTLV envelopes and their receptor GLUT1, the ubiquitous glucose transporter: a new vision on HTLV infection
Rakotobe et al. Human Polycomb group EED protein negatively affects HIV-1 assembly and release
Hübner et al. Inhibition of viral assembly in murine cells by HIV-1 matrix
Tokunaga et al. The cellular kinase binding motifs (PxxP and RR) in human immunodeficiency virus type 1 Nef protein are dispensable for producer-cell-dependent enhancement of viral entry
FR2897062A1 (fr) Domaine peptidique necessaire a l'interaction entre l'enveloppe d'un virus appartenant au groupe d'interference de herv-w et un recepteur asct
Janardhan Identification of immediate downstream effectors of HIV-1 Nef in T lymphocytes
Coil Roles of phosphatidylserine in enveloped virus infection